Amprion

Amprion is a precision-diagnostics company using Seed Amplification Assay (SAA) technology to detect misfolded proteins - alpha-synuclein, amyloid-beta and tau - in cerebrospinal fluid, giving physicians and drug developers a biological readout of neurodegenerative disease years before symptoms fully emerge. Its flagship SAAmplify-aSYN test (formerly SYNTap) is the first commercially available validated alpha-synuclein SAA, carries an FDA Breakthrough Device Designation, and aims to replace symptom-based guesswork for Parkinson's, Lewy body dementia, Alzheimer's and multiple system atrophy with autopsy-grade certainty.